Development of a high-performance immunolatex based on “soft landing” antibody immobilization mechanism by Yuan Xiaofei et al.
Development of a high-performance immunolatex
based on “soft landing” antibody
immobilization mechanism
著者 Yuan Xiaofei, Fabregat Dolca, Yoshimoto
Keitaro, Nagasaki Yukio
journal or
publication title
Colloids and surfaces. B, Biointerfaces
volume 99
page range 45-52
year 2012-11
権利 (C) 2011 Elsevier B.V.
NOTICE: this is the author's version of a work
that was accepted for publication in Colloids
and surfaces. B, Biointerfaces. Changes
resulting from the publishing process, such as
peer review, editing, corrections, structural
formatting, and other quality control
mechanisms may not be reflected in this
document. Changes may have been made to this
work since it was submitted for publication. A
definitive version was subsequently published
in Colloids and surfaces. B, Biointerfaces,
Volume 99, 2012.
DOI:10.1016/j.colsurfb.2011.09.040.
URL http://hdl.handle.net/2241/117627
doi: 10.1016/j.colsurfb.2011.09.040
1 
 
Development of a high-performance immunolatex 
based on “soft landing” antibody immobilization 
mechanism 
Xiaofei Yuan1,2,3, Dolça Fabregat5, Keitaro Yoshimoto2 and Yukio Nagasaki1,2,3,4*  
1Department of Materials Sciences, Graduate School of Pure and Applied Sciences, University 
of Tsukuba; 2Tsukuba Advanced Research Alliance (TARA), and 3Master School of Medical 
Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba; 
4Satellite Laboratory of International Center for Materials Nanoarchitectonics (MANA) in 
National Institute for Materials Science (NIMS), University of Tsukuba, Tennodai 1−1−1, 
Tsukuba, Ibaraki 305-8573, Japan; and 5Biokit Latex R&D Department, 
08186 Lliçà d'Amunt, Barcelona, Spain. 
*To whom correspondence should be addressed.  
Tel: +81-29-853-5749; Fax: +81-29-853-5749; E-mail:yukio@nagalabo.jp  
Abstract: Rabbit anti-human ferritin (anti-hFT) polyclonal immunoglobulin G (IgG) and 
poly(ethylene glycol) (PEG) were sequentially co-immobilized onto polystyrene 
submicroparticles (sMPs) to construct sMP/anti-hFT/PEG (SAP) immunolatex. Chemical 
immobilization of anti-hFT was performed at different pH levels to evaluate variations in 
antigen recognition. Basic pH disfavored conjugation of anti-hFT to sMPs, but remarkably 
increased its antigen recognition in comparison to that at neutral pH. We investigated this 
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intriguing phenomenon further by assessing the kinetics of antibody binding, including the 
time-dependency of immobilization, antigen recognition, and orientation of bound anti-hFT. 
Therefore, we attributed high antigen recognition to significant electrostatic repulsion 
between sMPs and anti-hFT at basic pH, which predominately prevented anti-hFT access to 
sMPs and concurrently promoted anti-hFT orientations suitable for antigen recognition. 
Subsequent PEG modification maintained such anti-hFT orientation, without which 
antigen-accessible orientations would have decreased with time. Thus, properly oriented 
antibody and immediate PEGylation after antibody immobilization contributed to the 
formation of a high-performance SAP immunolatex.  
Keywords: Antibody immobilization, Antibody orientation, PEGylation, Immunolatex, 
Immunoassay, Immunoreactivity 
1. Introduction 
With the development of biotechnology and nanotechnology, immobilized proteins, 
especially antibodies and enzymes, have been widely used as biosensors [1], microarrays 
[2-5], and immunoparticles [6-8]. These applications require immobilized proteins to maintain 
their conformation and proper active site orientation toward the bulk solution. Protein 
immobilization, however, is a complicated process, mainly owing to the unique structural 
features of proteins, such as diversity, flexibility, and amphiphilic surface, thereby making the 
process difficult to control. 
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Antibody immobilization consists of physical adsorption and chemical binding, which 
depends on the driving force. The former is simple, but nonspecific attractive forces easily 
cause antibody desorption [9]. Chemical binding was proposed as a solution because stable 
covalent linkages with antibodies are formed. However, it likely results in random antibody 
conjugation, accompanied by reduced antigen recognition and/or denaturation [10,11]. 
Accordingly, controllable covalent binding with proper antibody orientation is crucial for 
desirable antibody immobilization. To date, much effort has been devoted to this challenging 
task. Several traditional methods have been developed, such as disulfide bonds at the constant 
moiety (Fc region) of IgG antibodies [12,13], site-specific modification of carbohydrates in 
the Fc region [14], acid pretreatment promoting the preferential Fc adsorption [15-17], and 
attachment via Fc-recognizing protein A [18] or protein G [19]. Use of these methods has 
resulted in some success in manipulating antibody orientation for efficient antibody–antigen 
interactions. From the viewpoint of industrial applications, however, all these strategies are 
still economically unfeasible because of complexity and length, coupled with the laborious 
procedures and special techniques involved in these strategies.  
Versatile driving forces work during antibody physisorption, dependending on the features 
of antibodies and substrates [20-23], and the electrostatic interaction between them is one of 
the most important forces. Previous studies have shown that both the amount of immobilized 
antibodies and their orientation are affected by electrostatic interactions [21,22,24,25]. 
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Simulation of antibody adsorption and orientation on a charged surface was also performed to 
support this kind of orientation control [23]. Even with chemical binding, the orientation of an 
antibody may be dramatically influenced by its physisorption properties. These properties are 
dependent on the substrate, because antibodies generally need to undergo physisorption prior 
to covalent conjugation [26]. We predict that controlling the interaction between antibodies 
and the substrate surface, by charging character of solid surface with proper pH, ionic strength, 
etc., may easily adjust the orientation of the antibody during chemical binding. Thus, 
combining physical orientation control with robust chemical linkage between antibodies and 
substrates is an efficient strategy for desirable antibody immobilization.  
In this study, rabbit anti-human ferritin (anti-hFT) polyclonal immunoglobulin G (IgG) was 
chemically co-immobilized with poly(ethylene glycol) (PEG) onto polystyrene 
submicroparticles (sMPs) for development of sMP/anti-hFT/PEG (SAP) immunolatex. 
(Scheme 1) To optimize its performance, the effects of immobilization conditions on anti-hFT 
were evaluated in detail with respect to the degree of immobilization, antigen recognition, and 
orientation. Electrostatic repulsion between anti-hFT and sMPs at basic pH inhibited anti-hFT 
access to the sMP surface, but promoted its antigen-accessible orientation on the surface, 
resulting in high antigen recognition capacity of immobilized anti-hFT (named “soft landing” 
mechanism). Both the “soft landing” mechanism and subsequent PEGylation, which maintain 
the co-immobilized antibody’s orientation, are indispensable for constructing a 
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high-performance SAP immunolatex.   
2. Materials and methods 
2.1 Materials. Aqueous suspension of carboxylated polystyrene sMPs (10% w/v, without 
surfactant) [27,28], bovine serum albumin (BSA), rabbit anti-human ferritin (anti-hFT) 
polyclonal IgG ( 9.76 mg/mL, pH7.0, isoelectric point (pI) = 6~7), human ferritin (hFT) from 
spleen, and human sera from patients with rheumatoid arthritis (containing 29 ng/mL 
rheumatoid factor (RF); lot XI1005) and from healthy persons (without RF) were a kind gift 
from Biokit S.A. (Barcelona, Spain). According to the manufacturer’s data, the surface charge 
density of the sMPs is 25.67 µC cm-2, and the area occupied by each carboxyl functional 
group is 62.4 Å2. The particle size (251 nm) and electrophoretic mobility (µe = -4.45 
µmcm/Vs) of the sMPs in borate buffer solution (10 mM, pH 8) were measured on a Malvern 
Zetasizer Nano ZS instrument (He-Ne laser, U.K.). α-Methoxy-poly(ethylene 
glycol)-pentaethylenehexamine (mPEG-N6, Mn = 6000 g/mol; Scheme 1a) [27,28] aqueous 
solution (2% w/v, pH 10) was provided by JSR Co. (Tokyo, Japan). Unless otherwise stated, 
mPEG-N6 was always diluted in phosphate buffer (PB, pH 7.4) and 0.01 M HCl to achieve a 
final concentration of 0.3% w/v (8 mM PB, pH 7.4). 
1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC, special grade) and 
2-morpholinoethanesulfonic acid (MES) were provided by Kanto Chemical Co., Inc. (Tokyo, 
Japan) and Dojindo Laboratories (Kumamoto, Japan), respectively. All buffers used in this 
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study were prepared from sodium salts, deionized water (Millipore Milli-Q), and 1 M NaOH 
aqueous solution for pH adjustment. Unless otherwise stated, all experiments were performed 
at 25ºC or room temperature.  
2.2 Methods 
2.2.1 Antibody immobilization at different pH levels and salt concentrations. 
 To estimate the effect of ionic strength by salt addition, low-concentration buffer solutions 
(ionic strength, I = 0.6 mM) were used in this experiment. As previously reported [27],  a 
stoichiometric amount of EDC aqueous solution (3 µL, 12.5 mg/mL, EDC/COOH of sMPs = 
1) was added to a mixture of and sMP suspension (30 µL) and MES buffer (167 µL, 3 mM, 
pH 5.5) to activate sMP carboxyl groups. The mixture was then shaken for 20 min. The 
EDC-activated sMPs (30 µL, with active ester groups on the surface) were further diluted 
with 263 µL of PB (pH 7.4, I = 0.6 mM, containing 0–18 mM NaCl) or borate buffer (pH 
8.0–9.5 with the same I and NaCl concentration) to alter the pH and/or salt concentration. 
Then, freshly diluted anti-hFT in corresponding buffer (9 μL, 1 mg/mL) was fed and 
incubated for 1 h to allow the immobilization reaction between amine residues and the sMP 
active ester groups to occur. Low pH (<7.4) was unsuitable for this study.  
After anti-hFT immobilization, the sMP/anti-hFT conjugates (sensitized sMPs) were 
separated by centrifugation (15,000 rpm for 20 min at 25ºC; KR-20000; KUBOTA Co., 
Tokyo, Japan). A Micro BCA protein assay kit (#23235; Thermo Fisher Scientific Int., IL) 
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was used to quantify both sMP-bound and free anti-hFT, as previously reported [27]. 
To measure the reactivity of bound anti-hFT with a high signal-to-noise ratio and to 
colloidally stabilize the sensitized sMPs for various experiments, the residual bare sMP 
surfaces after antibody binding were further covered with mPEG-N6 for 30 min to form the 
sMP/anti-hFT/PEG immunolatex (SAP) through the covalent reaction between multiple 
mPEG-N6 amine end groups (0.3% w/v in 0.27 mM PB, pH 7.4) and the active ester groups 
on the surface. In this treatment, the final sMP and mPEG-N6 concentrations were both 0.1% 
w/v. The SAP immunolatex preparation protocol is illustrated in Scheme 1b. The resulting 
SAP immunolatex was centrifuged at 60,000 rpm for 20 min at 25ºC (CS 150GX; Hitachi 
Koki Co. Ltd., Japan) to eliminate unbound antibody in the supernatant, which would 
otherwise competitively recognize antigens during the reactivity assay. The collected purified 
SAP immunolatex was homogeneously resuspended in borate buffer (pH 8.0, 10 mM, 
containing 0.9 g/L NaN3) by ultrasonication (35 W, 60 Hz, ~20 s for several rounds), 
followed by storage at 4ºC for 1 day before use. Note that all the SAP immunolatex samples 
prepared at different pH levels were monodispersed and similar in size (261–268 nm). We did 
not observe any variations in these properties before and after redispersion prior to reactivity 
measurements.  
On the basis of the results of these experiments, buffer concentrations were optimized and 
used in the following experiments to enhance buffering capability without promoting 
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aggregation of sensitized sMPs. 
2.2.2. Effects of antibody-binding time. 
 EDC-activated sMPs (1.24 mL) were diluted in 10.85 mL of borate buffer (buffer A, pH 
9.5, 9 mM, I = 6 mM) or PB (pH 7.4, 2.7 mM, I = 6 mM) to alter the pH, followed by 
addition of freshly diluted anti-hFT dissolved in the same buffer (372 µL, 1 mg/mL) for 
immobilization. After 1, 5, 10, 20, 30, 60, and 90 min, the suspension (300 µL) was removed 
and centrifuged (15,000 rpm, 4 minÍ2 or 10 minÍ1, 25ºC; KR-20000; KUBOTA Co., 
Tokyo, Japan) to obtain the supernatant (250 µL), which was used to quantify free antibodies 
with the Micro BCA assay. Alternatively, the construction and purification of SAP 
immunolatex for immunoreactivity measurements was carried out as previously described. 
SAP immunolatex separately prepared at pH 7.4 and pH 9.5 are referred to as SAP(7.4) and 
SAP(9.5), respectively. 
  After PEGylation, free anti-hFT content was checked to confirm released antibody after 
immunolatex formulation. To exclude the contribution from mPEG-N6, which also gave 
some color in the assay [27], PEGylated EDC-activated sMPs without antibodies were used as 
a control. This is a reasonable treatment because mPEG-N6 weakly colored the assay and the 
coupled mPEG-N6 was present at low concentations [27]. 
2.2.3. Immunoreactivity measurements. 
We measured the immunoreactivity of purified SAP immunolatex with an automatic Biokit 
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Quantex Analyser (BQA 5802–0149; Furuno Electric Co., Ltd., Japan) on the basis of the 
particle-enhanced immunoagglutination phenomenon. (Scheme 2) Briefly, a given amount of 
hFT (30 µL, pH 7.0, containing 50 mM Tris, 1 g/L NaN3, 100 mM NaCl, and 10 g/L BSA) at 
room temperature was mixed with assay buffer at 8ºC (190 µL, PB buffer, pH 7.4, 10 mM, 
containing 1 g/L BSA and 0.9 g/L NaN3) in a cuvette at 37ºC. Then, SAP immunolatex (50 
µL, at 8ºC; sMPs concentration: 0.1% w/v) was added in and mixed well immediately. The 
increment in the absorbance at 570 nm (ΔAbs570nm), which was generated from the rapid 
agglutination of particles specifically triggered by antibody–antigen recognition, was 
monitored immediately for ~3 min and defined as the immunolatex immunoreactivity. 
2.2.4. Circular dichroism (CD) and fluorescence measurements. 
After an original anti-hFT solution was diluted in buffers (I = 6 mM) at different pH levels 
(pH = 7.4, 8.5, and 9.5), circular dichroism (CD) and fluorescence spectra were monitored 
every 10 min for 1 h. To avoid pH changes during the assay, the cell was sealed with parafilm. 
The CD spectra were recorded on a J-720W spectropolarimeter (Jasco, Japan), with a 1-mm 
quartz cell for far-ultraviolet radiation (260 to 200 nm) and a 10-mm quartz cell for 
near-ultraviolet radiation (320 to 260 nm) in a temperature-controlled (25ºC) cuvette holder. 
The anti-hFT concentrations were 0.1 and 1 mg/mL, respectively. The scan speed was 200 
nm/min, which was the average of 10 scans for each measurement. The CD spectra were 
corrected for the buffer blank, and the mean residue ellipticities were calculated using a value 
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of 110 for the mean residue weight. The fluorescence spectra for anti-hFT were recorded at a 
concentration of 0.5 mg/mL on an F-7000 fluorometer (Hitachi High-Technologies Co., 
Japan), with a 1-cm quartz cell in a temperature-controlled (25ºC) cuvette holder. The 
excitation wavelength was 280 nm, and the emission spectrum was between 290 to 450 nm. 
2.2.5. Orientation assay of bound anti-hFT.  
The orientation assay of bound anti-hFT was performed on a PL-2500 spectrophotometer 
(Shimadzu, Japan). Briefly, a given amount of human serum containing 29 ng/mL of RF was 
poured into PB buffer (pH 7.4, 10 mM) to a final volume of 450 µL. Then, 50 µL of purified 
SAP immunolatex (sMPs concentration of 0.1% w/v) was added and mixed well, and the 
absorbance was immediately monitored at a wavelength of 550 nm for 5 min at room 
temperature. Because RF is an IgM antibody, which comprises multiple units specific for 
recognizing the Fc region of human and rabbit IgG [29,30], it may agglutinate the SAP 
immunolatex containing rabbit anti-hFT with the Fc region facing outward, which we term 
the “head-on” orientation shown in Scheme 3. The absorbance thus increased because of the 
assembled SAP particles. The higher the absorbance increment (ΔAbs550nm) within a 5 
min-period, the more “head-on” orientated bound anti-hFTs the SAP immunolatex has. In a 
parallel experiment, human serum without RF was used to confirm that RF specifically 
triggered SAP immunolatex agglutination. 
2.2.6. Dynamic light scattering (DLS) and electrophoretic mobility (µe) measurements.  
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A Malvern Zetasizer Nano ZS instrument (He-Ne laser, 633 nm, Worcestershire, U.K.) was 
used for dynamic light scattering (DLS) and electrophoretic mobility (µe) measurements at 
25ºC. All test samples were measured after dilution in borate buffer (pH 8.0, 10 mM, I = 0.6 
mM) to a final sMP concentration of approximately 2.5Í10-3% w/v. Notably, the borate 
buffer’s low ionic strength is a prerequisite for evaluating the variation in µe values; otherwise, 
the surface charge will be thoroughly screened by ions. Each measurement was repeated at 
least 4 (DLS) or 3 (µe) times, and the mean value was reported as the result. 
2.2.7. Statistics analysis.  
The results shown in this study are all expressed as average ± S.D. (n = 3), except for the 
CD and fluorescence measurements. P values were calculated based on the t-test analysis.  
3. Results  
3.1. Antibody immobilization at different pH levels.  
To evaluate the effects of pH on antibody immobilization, anti-hFT was chemically bound 
to sMPs in buffers (I = 0.6 mM without salt) at several pH levels. The amounts of both bound 
and unbound anti-hFT were then quantified. Figure 1a shows the pH-dependent amounts of 
free (Γf) and bound anti-hFT (Γb) in the system before PEGylation, as calculated with the 
Micro BCA assay. As the Γf increased, the Γb gradually decreased with increasing pH. These 
results confirm that high pH values disfavor anti-hFT immobilization, in agreement with the 
results of previous reports, which show that the maximum amount of adsorbed proteins 
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appeared at a pH value close to the pI [21,22,25].  After PEGylation to construct the SAP 
immunolatex, immunoreactivity measurements were performed at a range of antigen 
concentrations. Figure 1b summarizes the SAP immunolatex immunoreactivity, which 
reflects the antigen recognition of immobilized anti-hFT. Interestingly, SAP immunolatex 
immunoreactivity increased with increasing pH, contrary to the Γb decrease stated above. For 
example, the SAP immunoreactivity at pH 9.5 is twice that at pH 7.4 with an hFT 
concentration of 56 ng/mL, as shown in the insert in Figure 1b.  
3.2. Circular dichroism (CD) and fluorescence measurements. 
 Because proteins, such as antibodies, are susceptible to changes in environments, it is 
important to confirm structural changes during modification treatment. Both the anti-hFT CD 
and fluorescence spectra were monitored at 10-min intervals, following the dilution of the 
original anti-hFT into buffers at different pH levels, similar to the anti-hFT dilution treatment 
just before antibody immobilization. Figure 2 shows the anti-hFT far-ultraviolet and 
near-ultraviolet CD spectra, which were recorded immediately after anti-hFT dilution. These 
CD spectra showed no environment-induced changes even at the 60-min time point (Fig. S1 
in Supporting Information). Anti-hFT fluorescence spectra did not vary, regardless of pH and 
time point (Fig. S2 in Supporting Information). The far- and near-ultraviolet CD are sensitive 
to variations in secondary and tertiary protein structures, respectively, and fluorescence 
intensity and maximum wavelength are also suitable indicators of changes in tertiary structure 
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[31]. These results show that the anti-hFT structure did not change within 60 min at different 
pH levels. 
3.3. Effects of antibody-binding time. 
 To gain an insight into the high anti-hFT antigen recognition at basic pH, anti-hFT 
immobilization at a series of binding times was separately carried out at pH 7.4 and 9.5. 
Figure 3 shows the Γb values both before and after PEGylation, which represents the amount 
of surface antibody after the immobilization reaction (Fig. 3a) and after PEGylation (Fig. 3b). 
Before PEGylation (Fig. 3a), almost all anti-hFT was bound to sMPs at pH 7.4, which was 
observed even after 1 min (theoretical Γb for complete binding = 29.9 µg/mL), resulting in a 
nearly constant Γb. On the contrary, binding at pH 9.5 proceeded slowly, and free anti-hFT 
remained after 90 min. These data clearly suggest that the anti-hFT adsorption rate is 
extremely high at pH 7.4, but low at pH 9.5. After PEGylation (Fig. 3b, theoretical Γb for 
complete binding = 19.9 µg/mL), large amounts of pre-bound anti-hFT were unexpectedly 
liberated from sMPs, especially those with short binding times (<20 min). Consequently, Γb 
displayed a similar time-dependency at both pH 7.4 and 9.5. Considering the experimental 
error (see Materials and methods), the slight difference in Γb between SAP(7.4) and SAP(9.5) 
was negligible. Release of antibody was triggered by PEGylation because anti-hFT release 
from sMPs was not observed following addition of PB (pH 7.4, 8 mM) (Fig. S3 in Supporting 
Information). Probably, a large amount of mPEG-N6 competitively replaced weakly adsorbed 
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antibodies before their covalent linkage formation, especially the case with short binding time.   
Figure 4 shows the antigen recognition to bound anti-hFT as a function of the 
antibody-binding time. The recognition of SAP(9.5) was much higher than that of SAP(7.4), 
particularly at short binding times and high antigen concentrations. Although the SAP(7.4) 
and SAP(9.5) Γb values increased with time up to 90 min (Figure 3b), we did not observed a 
significant increase in antigen recognition, especially for SAP prepared with a long 
antibody-immobilization time. Excessive antibody immobilization [32] has been shown to 
decrease antigen recognition because of steric restriction. However, in our experiments, the 
reactivity increased at higher concentrations of immobilized antibody (Fig. S4 in Supporting 
Information). The different antigen affinities clearly indicate that the amount of 
immobilization antibody is not responsible for the high SAP(9.5) immunoreactivity.   
3.4. Orientation assay of immobilized anti-hFT.  
As described in the Materials and methods, RF IgM may specifically recognize the 
anti-hFT Fc region. Therefore, the high ΔAbs550nm value denotes that the SAP immunolatex 
contains more “head-on” orientated anti-hFT molecules (Scheme 3). Figure 5a shows the 
SAP(7.4) and SAP(9.5) ΔAbs550nm values, both with an antibody-immobilization time of 20 
min, as a function of the volume of RF-containing human serum. Although the 2 values 
increased with an increase in the RF amount, the ΔAbs550nm value was much higher for 
SAP(7.4) than for SAP(9.5) under the same conditions. The SAP immunolatex ΔAbs550nm 
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value obtained with human serum without RF is zero, regardless of the amount of human 
serum used. The results confirm that RF specifically agglutinated the SAP immunolatex and 
that SAP(7.4) contained more nonreactive “head-on” orientated anti-hFT than did SAP(9.5). 
Notably, SAP(7.4) and SAP(9.5) used in this experiment had the same Γb (Fig. 3b). Thus, 
their different ΔAbs550nm values reflect different orientation states of bound anti-hFT. The 
correlation between the ΔAbs550nm value of SAP immunolatex and the antibody-binding time 
was then estimated using the same amount of RF (3 µL of RF-containing human serum), and 
the resultant correlation profiles are summarized in Figure 5b. Unike the ΔAbs550nm of 
SAP(7.4), which increased immediately after antibody immobilization, the SAP(9.5) 
ΔAbs550nm increased only at the later time points in the antibody-immobilization experiment, 
suggesting that a long antibody-binding time tends to cause orientation changes under alkaline 
conditions. Figure 5c provides the ΔAbs550nm  Γb-dependency calculated from the results 
shown in Figures 5b and 3b, for which linear and concave upward Γb-dependency curves were 
separately obtained for SAP(7.4) and SAP(9.5). On the basis of this data, we suggest that the 
antibody that immobilized under alkaline conditions was probably highly oriented. Its 
orientation, however, gradually changed during the immobilization process under the same 
conditions. 
3.5. Electrophoretic mobility (µe) measurements. 
 We tested the SAP immunolatex electrophoretic mobility (µe) to obtain further information 
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about the antibody’s surface, and we observed some intriguing phenomena. The SAP 
immunolatex µe is presented as a function of the antibody-binding time (Fig. 6a) and of its Γb 
(Fig. 6b). The  µe value of SAP(9.5) was much higher than that of SAP(7.4) at a binding time 
of 1 min. However, this value continuously decreased over time in the case of SAP(9.5), 
while we did not observed a change in the µe value of SAP(7.4). Finally, the  µe values for 
SAP(7.4) and SAP(9.5) became equal. A rapid decrease in the  µe value of SAP(9.5) occurred 
at Γb > 10 µg/mL, accompanied with an invariable µe value of SAP(7.4). Proteins tend to 
change their conformation to spread on the surface after binding with each other to enhance 
their interaction [14], and adsorption retardation, such as that at pH 9.5, further promoted this 
tendecy [24]. Because of the conformational changes in the antibody after a prolonged 
antibody-immobilization phase, the remaining surface might be significantly reduced, thereby 
restricting subsequent PEGylation and resulting in a decreased µe value. We assumed that the 
relatively low PEGylation effectiveness at neutral pH, in comparison with that at basic pH 
[33], accounts for the constant low SAP(7.4)  µe values. Otherwise, a dense PEG layer might 
efficiently shield the surface charge to give a high µe value. Actually, we found that the µe 
values of PEGylated sMPs (sMP/PEG complex) under the same conditions without antibody 
were –2.4 (at pH 9.5) and –2.7 (at pH 7.4) µm cm/Vs, and both values were almost constant 
within 60 min. The PEGylation results will be reported elsewhere. 
4. Discussion 
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As described in the Introduction, the physisorption properties of anti-hFT might play an 
important role in its chemical immobilization reaction. On the basis of the sMP surface and 
anti-hFT (pI = 6 ~ 7) characteristics, the hydrophobic effect and the electrostatic interactions, 
in particular, are crucial for efficient anti-hFT adsorption. Compelling evidence was obtained 
from the anti-hFT immobilization at pH 9.5 in the presence of salt (3–9 mM NaCl). Γb 
significantly increased as salt concentration increased, whereas no variation was observed in 
Γb at pH 7.4 under the same conditions (Table S1 in Supporting Information). Salt decreased 
the electrostatic repulsive force between anionic anti-hFT and the negatively charged sMP 
surface at high pH, confirming that the electrostatic repulsive force retards the access of the 
antibody to the sMP surface under alkaline conditions.  
Generally, there are three possibilities that may account for increased immunoreactivity: (1) 
a net increase in antibody’s antigen recognition before immobilization, (2) increased antibody 
immobilization (or antibody-surface concentration), and (3) changes in the orientation of 
bound antibodies [16,17,26]. With regards to an increase in binding recognition, we evaluated 
structural variations in anti-hFT in terms of time-dependent circular dichroism (CD) and 
fluorescence spectra at different pH levels. We did not observe any variation in the anti-hFT 
structure within 60 min. (Fig. 2) Since the anti-hFT dilution was usually performed less than 5 
min before immobilization, the structure of anti-hFT should not have changed significantly. 
Moreover, the whole SAP immunolatex preparation, including both antibody immobilization 
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and PEGylation, took place over the course of an hour. Therefore, increased antigen 
recognition of anti-hFT prior to immobilization seems unlikely. An increased amount of 
surface antibody is also unlikely because SAP(7.4) and SAP(9.5) had similar Γb values 
despite the difference in the antibody binding time (Fig. 3b). To ascertain whether changes in 
orientation could account for our results, the orientation of bound anti-hFT was directly 
analyzed with human serum containing Fc-region-recognizable RF. As shown in Figure 5b, 
the initial SAP (9.5) ΔAbs550nm value was much lower than that of SAP(7.4) (Γb < 10 µg/mL), 
suggesting the presence of differently oriented immobilized antibodies at pH 7.4 and pH 9.5. 
As the amount of immobilized antibody increased, however, more SAP(9.5)-derived anti-hFT 
molecules with Fc regions facing outward gradually appeared on the surface (Fig. 5c), 
confirming that the increased amount of pre-bound antibody changed the orientation of 
post-bound one. Moreover, the µe values of SAP(9.5) further supported our results. The 
Γb-dependent µe value (Fig. 6b) and ΔAbs550nm (Fig. 5b) of SAP(9.5) were mostly constant at 
Γb < 10 µg/mL before continuous variation.  
On the basis of these results, it is plausible that the differences in immunoreactivity 
between SAP(7.4) and SAP(9.5) originated from different orientations of bound anti-hFT. At 
pH 7.4, almost neutral anti-hFT might strongly prefer hydrophobic attractions with sMPs, 
resulting in an extremely rapid or instant adsorption process and random orientation (Scheme 
4a). The enhanced electrostatic repulsive force at pH 9.5 compensated for the hydrophobic 
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interaction, retarding anti-hFT adsorption onto the negatively charged surface. In principle, 
IgG adsorption preferentially occurs with its Fc region on the hydrophobic surface, owing to 
its hydrophobic characteristics and/or the structural instability over the IgG antigen-binding 
region (F(ab’)2) [24]. Additionally, the anti-hFT F(ab’)2 region (pI = ~5.6) [34] should be 
negatively charged at high pH and electrostatically repelled from sMPs. Thus, retardation of 
anti-hFT adsorption may provide time for anti-hFT orientation changes, such as the change to 
the “end-on” orientation (Fc region close to the surface as shown in Scheme 3), which favor 
antibody-antigen recognition (Scheme 4b). We named this the “soft landing” mechanism. It 
should be emphasized here that subsequent PEGylation played a key role in maintaining the 
immobilized antibody’s orientation, as reported previously [13].  However, this situation 
changed as the amount of surface antibody increased, probably because of weakened 
repulsive forces, leading to randomly oriented bound antibody similar to that found at pH 7.4. 
In addition, the pre-bond antibodies might also change orientation and/or conformation at 
longer antibody-binding times before PEGylation, thus losing antigen recognition [13]. 
Consequently, SAP(9.5) showed higher antigen recognition than SAP(7.4), but both values 
remained constant at later time points. (Fig. 4)  
5. Conclusion 
By physically manipulating anti-hFT orientation during chemical immobilization, we 
successfully formed a high-performance SAP immunolatex. The detailed study on anti-hFT 
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immobilization with respect to the extent of immobilization, antigen recognition, and 
anti-hFT orientation, supports the idea of a rapid blocking effect of PEGylation following 
short-term antibody immobilization. This effect benefited from the combination of physical 
adsorption and covalent binding of antibodies. Physical adsorption may have resulted in facile 
orientation changes and covalent binding may have anchored antibodies robustly, unlike 
traditional time-consuming antibody immobilization protocols. Moreover, the consistency of 
the Γb-dependent variations in antibody orientation and the SAP immunolatex µe values 
implies that electrophoretic mobility measurements probably provide a convenient indirect 
approach to investigate antibody orientation, which relies on the inherent structural nature of 
the antibody/PEG hybrid layer on sMPs. It should be mentioned here that the proper pH level 
for obtaining proper antibody orientation may be adjusted down to close to antibody’s PI by 
using highly charged sMPs, if antibodies are not stable enough at high pH level during the 
binding process. Thus, although more experiments are still required, the “soft landing” 
mechanism proposed in this study seems a general rule for antibody binding and will attract 
more attention as a useful tool in the near future.  
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Figure Captions 
Scheme 1. (a) Chemical structure of mPEG-N6 and (b) SAP immunolatex construction. 
Scheme 2. Schematic representation of the immunoreactivity assay used in this study. 
Scheme 3. Schematic illustration of the specific interaction between rheumatoid factor (RF) 
and the Fc region of bound anti-hFT. 
Scheme 4. Proposed mechanism of anti-hFT immobilization at (a) pH7.4 and (b) pH9.5. 
Figure 1. (a) pH-dependent antibody amount of immobilized anti-hFT (Γb, ) and free 
anti-hFT (Γf, ) in the system before PEGylation measured by Micro BCA assay. (b) 
Immunoreactivity of SAP immunolatex as a function of hFT concentration (left) and 
pH-dependent immunoreactivity of SAP immunolatex measured at hFT = 56 ng/mL (right).  
The SAP immunolatex was prepared by immobilizing anti-hFT at pH7.4 (¯), pH8 (r), 
pH8.5 (£), pH9 (), and pH9.5 (Í), respectively. Ú and # : P < 0.001 separately vs. that at 
pH7.4 ; ×: P < 0.05 vs. that at pH8.0; +: P < 0.05 vs. that at pH8.5 based on t-test analysis (n = 
3). 
Figure 2. (a) Far-ultraviolet and (b) near-ultraviolet CD spectra recorded immediately 
(holding time t = 0) after dilution of anti-hFT in buffers at different pH levels. Solid line (─), 
dotted line (….), and broken line (----) represent the spectra of anti-hFT in a buffer (I = 6 
mM) of pH = 7.4, 8.5, and 9.5, respectively. 
Figure 3. (a) Time-dependent anti-hFT quantities of sensitized sMPs before PEGylation, and 
its fraction of the total (Γb/(Γb+Γf)), as antibody binding was performed at pH7.4 (r) and 
pH9.5 (), respectively. (b) Time-dependent anti-hFT quantities and its fraction of the total 
(Γb/(Γb+Γf)) after the construction of SAP(7.4) (r) and SAP(9.5) (), respectively. (n= 3) 
Figure 4. Correlation between anti-hFT binding time and SAP(7.4) (a) and SAP(9.5) (b) 
immunoreactivity, respectively. Immunoreactivity measurements were performed at hFT 
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concentrations of 11 (r and p), 22 (¯ and ¿), and 56 ng/mL ( and ), respectively. Ú1, 
#1, and +1: P < 0.01 separately vs. that of SAP(7.4) with antibody binding time = 1 min; Ú2, #2, 
and +2: P < 0.05 separately vs. that of SAP(9.5) with antibody binding time = 1 min, both 
based on t-test analysis (n = 3). 
Figure 5. (a) Variations in the ΔAbs550nm value of SAP immunolatex (anti-hFT binding time = 
20 min) with human serum containing RF (open symbol) or not (close symbol); (b) 
Antibody-binding time dependent variations in SAP immunolatex ΔAbs550nm; (c) Γb-dependent 
ΔAbs550nm of SAP immunolatex. SAP(9.5) ( and ) ; SAP(7.4) (r and p). (n= 3) 
Figure 6. (a) Antibody-binding time dependent variations in electrophoretic mobility (µe) of 
SAP immunolatex. (b) Γb-dependent SAP immunolatex µe. SAP(7.4) (r);SAP(9.5) (). (n= 
3) 
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